title: Initial human feasibility study of DC ablation as a treatment for benign prostatic hyperplasia: 6 month follow-up data.
abstract: Direct current (DC) ablation is a novel non-thermal technology that causes focused coagulative necrosis in the lateral lobes of the prostate to treat benign prostatic hyperplasia (BPH). The necrosis is caused by a zone of non-physiologic pH which is created in a predictable pattern around each electrode in which a direct current is applied during treatment. The objective of this study was to optimize treatment parameters and assess treatment tolerability using transurethral DC ablation as an office-based treatment for BPH.
authors.affiliation: Urology at the Universidad de Chile, Santiago, Chile. jcabezas@redclinicauchile.cl
authors.forename: Juan S
authors.initials: JS
authors.lastname: Cabezas
authors.forename: Oscar A
authors.initials: OA
authors.lastname: Storme
authors.forename: Claudia
authors.initials: C
authors.lastname: Ramis
authors.forename: Benjamin R
authors.initials: BR
authors.lastname: Fruland
authors.forename: Kai
authors.initials: K
authors.lastname: Kroll
authors.forename: Thayne R
authors.initials: TR
authors.lastname: Larson
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017115:Catheter Ablation / Q000295:instrumentation* / Q000379:methods*; D004566:Electrodes; D004867:Equipment Design; D019544:Equipment Failure Analysis; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome